Moderna upgraded to Outperform from Market Perform at TD Cowen

TD Cowen upgraded Moderna to Outperform from Market Perform with a price target of $180, up from $150.While COVID "is approaching its tail," Moderna will be a leader in respiratory syncytial virus, the analyst tells investors in a research note. The firm expects the company’s flu data by month’s end to be "superior." Despite Moderna’s increased spending, the company should not have to raise cash, Cowen adds. With catalysts ahead, it believes the shares are more likely to go to $180 than $100.